🇺🇸 Atripla in United States

51,519 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Bone Density Decreased — 9,587 reports (18.61%)
  2. Chronic Kidney Disease — 5,891 reports (11.43%)
  3. Tooth Loss — 4,963 reports (9.63%)
  4. Renal Injury — 4,746 reports (9.21%)
  5. Renal Failure — 4,617 reports (8.96%)
  6. Bone Loss — 4,508 reports (8.75%)
  7. Osteonecrosis — 4,359 reports (8.46%)
  8. Pain — 4,309 reports (8.36%)
  9. Skeletal Injury — 4,275 reports (8.3%)
  10. Emotional Distress — 4,264 reports (8.28%)

Source database →

Other Other approved in United States

Frequently asked questions

Is Atripla approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Atripla in United States?

Professor Francois Venter is the originator. The local marketing authorisation holder may differ — check the official source linked above.